Kusatsu/Shiga, Japan — May 16, 2019 – Takara Bio Inc. (Takara Bio) announces that the results from the clinical trials of C-REV (canerpaturev, former HF10), an oncolytic viral immunotherapy and NY-ESO-1・siTCR™ gene therapy will be presented at the 2019 Annual Meeting of the American Society of Clinical Oncology (May 31 – June 4, 2019, Chicago, Illinois, U.S.).

Outline of presentation

Name of Conference

ASCO (American Society of Clinical Oncology) Annual Meeting 2019


McCormick Place (Chicago, Illinois, U.S.)


June 1, 8:00 am – 11 am (Local time)


Abstract ID 2610

Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without Ipilimumab (Ipi) for advanced solid tumor patients (pts)

⇒Clieck here for the poster

Abstract ID 2530

Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer

⇒Click here for the poster

Abstract ID 2537

Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS

⇒Clieck here for the poster

Takara Bio is developing the oncolytic virus C-REV and NY-ESO-1siTCR™ gene therapy products, aiming its swift commercialization. We are striving to meet the unmet medical needs and contribute to improving the health of people through the innovative products.